Skip Navigation



Human Molecular Genetics Advance Access published online on August 7, 2006
Human Molecular Genetics, doi:10.1093/hmg/ddl201
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
15/18/2690    most recent
ddl201v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Gawlik, K. I.
Right arrow Articles by Durbeej, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gawlik, K. I.
Right arrow Articles by Durbeej, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved
Received June 15, 2006
Revised July 27, 2006
Accepted July 27, 2006

Article

Laminin {alpha}1 chain improves laminin {alpha}2 chain deficient peripheral neuropathy

Kinga I. Gawlik 1, Jia-Yi Li 2, Åsa Petersén 2, and Madeleine Durbeej 3 *

1 Muscle Biology Unit, Division for Cell and Matrix Biology, Department of Experimental Medical Science, University of Lund, Lund, Sweden
2 Neuronal Survival Unit, Department of Experimental Medical Science, University of Lund, Lund, Sweden
3 Muscle Biology Unit, Division for Cell and Matrix Biology, Department of Experimental Medical Science, University of Lund, BMC B12, 221 84 Lund, Sweden

* To whom correspondence should be addressed.
Madeleine Durbeej, E-mail: madeleine.durbeej-hjalt{at}med.lu.se


  Abstract

Absence of laminin {alpha}2 chain leads to a severe form of congenital muscular dystrophy (MDC1A) associated with peripheral neuropathy. Hence, future therapies should be aimed at alleviating both muscle and neurological dysfunction. Pre-clinical studies in animal models have mainly focused on ameliorating the muscle phenotype. Here we show that transgenic expression of laminin {alpha}1 chain in muscles and the peripheral nervous system of laminin {alpha}2 chain deficient mice reduced muscular dystrophy and largely corrected the peripheral nerve defects. The presence of laminin {alpha}1 chain in the peripheral nervous system resulted in near normal myelination, restored Schwann cell basement membranes and improved rotarod performance. In summary, we postulate that laminin {alpha}1 chain is an excellent substitute for laminin {alpha}2 chain in multiple tissues and suggest that treatment with laminin {alpha}1 chain may be beneficial for MDC1A in humans.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
K. K. McKee, S. Capizzi, and P. D. Yurchenco
Scaffold-forming and Adhesive Contributions of Synthetic Laminin-binding Proteins to Basement Membrane Assembly
J. Biol. Chem., March 27, 2009; 284(13): 8984 - 8994.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
B. L. Patton, B. Wang, Y. S. Tarumi, K. L. Seburn, and R. W. Burgess
A single point mutation in the LN domain of LAMA2 causes muscular dystrophy and peripheral amyelination
J. Cell Sci., May 15, 2008; 121(10): 1593 - 1604.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. Xu, K. Chandrasekharan, J. H. Yoon, M. Camboni, and P. T. Martin
Overexpression of the Cytotoxic T Cell (CT) Carbohydrate Inhibits Muscular Dystrophy in the dyW Mouse Model of Congenital Muscular Dystrophy 1A
Am. J. Pathol., July 1, 2007; 171(1): 181 - 199.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.